The chikungunya virus is widespread in tropical regions, where it is spread to humans by mosquitoes of the genus Aedes. Chikungunya is characterized by high fever, headache, muscle and joint pain, rash, and sometimes diarrhea. ...
Nov 22, 2023
0
0
New tests of a recently approved vaccine for respiratory syncytial virus—RSV—show the shot remains effective against a range of variants producing potent antibody responses against current and past strains, and may even ...
Altered measles and mumps viruses could be used as a platform to create a trivalent COVID-19 vaccine that triggers immunity to multiple variant strains of the SARS-CoV-2 virus, new research in animals suggests.
Oct 2, 2023
0
31
Researchers from the University of Pittsburgh and the National Institutes of Health (NIH) Vaccine Research Center have developed an improved way to test potential vaccines against bird flu. The report was published this week ...
Sep 29, 2023
0
29
Studies of a "future-proof" vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals. The studies suggest that a single vaccine with combinations of these ...
Sep 25, 2023
0
46
Scientists have established the effectiveness of vaccines they developed to prevent the disfiguring skin disease leishmaniasis in animal studies, and Phase 1 human trial planning is in motion for the most promising candidate.
Aug 31, 2023
0
22
A vaccine candidate that can protect children from Meningococcal group B (MenB), which can lead to meningitis, has progressed to clinical development, according to an announcement by researchers from the University of Surrey ...
Jul 18, 2023
0
1
Researchers at the Paul-Ehrlich-Institut (PEI), in cooperation with the Philipps-Universität Marburg, used the "recombinant measles vaccine virus" vaccine platform to test vaccine candidates against the dangerous avian H7N9 ...
Jul 7, 2023
0
44
The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.
Jun 12, 2023
0
40
Animal studies indicate that a new COVID-19 vaccine developed at Rutgers may provide more durable protection against SARS-CoV-2 and its emerging variants than existing vaccines.
May 8, 2023
0
18
